CD21<sup>lo</sup> B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma

CD21<sup>lo</sup> B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma

Immune checkpoint inhibitor (ICI) therapy increases the risk of immune-related adverse events (irAEs). In particular, combination checkpoint blockade (CCB) targeting inhibitory CTLA-4 and PD-1 receptors could lead to irAEs at a higher rate than ICI monotherapy. Management of irAEs is important while...

Full description

Bibliographic Details
Main Authors: Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Journal of Personalized Medicine
Subjects:
immune checkpoint inhibitor
immune-related adverse events
CD21lo B cells
renal cell carcinoma
combination checkpoint blockade
Online Access:https://www.mdpi.com/2075-4426/12/6/888

Similar Items

Similar Items